Martin Gleave

Director, Vancouver Prostate Centre
Email Address 
Phone 
604.875.5603
Mailing Address 
Diamond Health Care Centre 6th floor, 2775 Laurel Street Vancouver, BC V5Z 1M9

Biography

Academic Appointment 
Professor
Body Locations and Systems 
Kidneys and Urinary System

Martin Gleave M.D., FRCSC, FACS

Liber Ero British Columbia Leadership Chair in Prostate Research, Director, The Vancouver Prostate Centre, Distinguished Professor and Vice-Chair, Department of Urologic Sciences, UBC Director of Research, Dept. of Urologic Sciences M.D. - University of British Columbia, 1984 Fellow of the Royal College of Surgeons of Canada (FRCSC), 1989 Urologic Oncology Fellow, University of Texas MD Anderson Cancer Center 1992 Fellow of the American College of Surgeons (FACS) 1998 RESEARCH INTERESTS

Dr. Gleave is a BC Leadership Chair and Distinguished Professor in the Department of Urologic Sciences at the University of British Columbia. He is the Director of the Vancouver Prostate Center, and CEO of the PC-TRIADD National Centre of Excellence in Commercialization and Research, where he leads a multidisciplinary team of 20 scientists and several research programs that bridge the innovation gaps that confront competitive knowledge translation and commercialization. He has published > 300 papers and attracted >$80M in research funding.

Dr. Gleave’s research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to abrogate the stress response to create conditional lethality and improve cancer control.

He patented several anti-cancer drugs and in 2001 founded OncoGenex Technologies, now a Nasdaq-listed biotechnology company for which he serves as Chief Scientific Officer. Dr Gleave developed OGX-011, an inhibitor of the cell survival gene, clusterin, that potentiates anti-cancer therapies in many cancer models. 7 clinical studies have been completed, including a randomized trial demonstrating a 7 month gain in overall survival when OGX-011 was combined with docetaxel. Two Phase III registration trials with OGX-011 began in 2010. OGX-427 is another agent targeting Hsp27 that completed Phase I studies in 2010, and a TFRI grant was supported in 2010 to support Phase II studies initiated in 2011.

Dr. Gleave is the recipient of numerous awards, including the NCIC's prestigious William Rawls Award for contributions to cancer control in Canada, the Society of Urologic Oncology’s Young Investigator Award, Finalist, Ernst and Young Entrepreneur of the Year, 2004, and Clinician-Scientist Award, Prostate Cancer Foundation. In 2003, he was appointed a Distinguished University Scholar at the University of British Columbia, and a BC Leadership Chair through the Province of BC’s Leading Edge Endowment Fund in 2005. Dr. Gleave was awarded the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.